Back

Systems-level immunomonitoring from acute to recovery phase of severe COVID-19

Rodriguez, L.; Pekkarinen, P.; Tadepally, L. K.; Tan, Z.; Rosat Consiglio, C.; Pou, C.; Chen, Y.; Habimana Mugabo, C.; Nguyen Quoc, A.; Nowlan, K.; Strandin, T.; Levanov, L.; Mikes, J.; Wang, J.; Kantele, A.; Hepojoki, J.; Vapalahti, O.; Heinonen, S.; Kekalainen, E.; Brodin, P.

2020-06-05 allergy and immunology
10.1101/2020.06.03.20121582
Show abstract

The immune response to SARS-CoV2 is under intense investigation, but not fully understood att this moment. Severe disease is characterized by vigorous inflammatory responses in the lung, often with a sudden onset after 5-7 days of stable disease. Efforts to modulate this hyperinflammation and the associated acute respiratory distress syndrome, rely on the unraveling of the immune cell interactions and cytokines that drive such responses. Systems-level analyses are required to simultaneously capture all immune cell populations and the many protein mediators by which cells communicate. Since every patient analyzed will be captured at different stages of his or her infection, longitudinal monitoring of the immune response is critical. Here we report on a systems-level blood immunomonitoring study of 39 adult patients, hospitalized with severe COVID-19 and followed with up to 14 blood samples from acute to recovery phases of the disease. We describe an IFN{gamma} - Eosinophil axis activated prior to lung hyperinflammation and changes in cell-cell coregulation during different stages of the disease. We also map an immune trajectory during recovery that is shared among patients with severe COVID-19. HIGHLIGHTSSystems-level immunomonitoring from acute to recovery in severe COVID-19 An IFN{gamma} - Eosinophil axis involved in lung hyperinflammation Cell-cell coregulation differ during four disease stages Basophils and hyperinflammation modulate humoral responses A shared trajectory of immunological recovery in severe COVID-19

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Nature Communications
based on 483 papers
Top 7%
10.9%
2
Nature Immunology
based on 14 papers
Top 0.1%
10.8%
3
Frontiers in Immunology
based on 140 papers
Top 0.9%
7.4%
4
Journal of Experimental Medicine
based on 10 papers
Top 0.1%
5.7%
5
Science Immunology
based on 15 papers
Top 0.1%
4.9%
6
Allergy
based on 13 papers
Top 0.5%
4.6%
7
Immunity
based on 11 papers
Top 0.1%
4.6%
8
The Journal of Immunology
based on 19 papers
Top 0.3%
4.6%
50% of probability mass above
9
Clinical Immunology
based on 12 papers
Top 0.2%
4.4%
10
Cell Reports Medicine
based on 49 papers
Top 1%
2.7%
11
Nature Medicine
based on 88 papers
Top 5%
2.4%
12
Journal of Clinical Investigation
based on 50 papers
Top 1%
2.4%
13
eLife
based on 262 papers
Top 12%
2.4%
14
Cell
based on 28 papers
Top 1%
2.3%
15
JCI Insight
based on 63 papers
Top 3%
1.7%
16
PLOS ONE
based on 1737 papers
Top 90%
1.5%
17
Journal of Allergy and Clinical Immunology
based on 15 papers
Top 1%
1.3%
18
Science Translational Medicine
based on 40 papers
Top 3%
1.3%
19
Cell Genomics
based on 34 papers
Top 3%
1.3%
20
iScience
based on 74 papers
Top 6%
1.2%
21
Clinical Infectious Diseases
based on 219 papers
Top 18%
1.2%
22
Communications Biology
based on 36 papers
Top 3%
1.2%
23
Journal of Clinical Immunology
based on 11 papers
Top 0.5%
1.2%
24
EBioMedicine
based on 21 papers
Top 2%
0.8%
25
Scientific Reports
based on 701 papers
Top 85%
0.8%
26
Proceedings of the National Academy of Sciences
based on 100 papers
Top 13%
0.8%
27
Clinical & Translational Immunology
based on 14 papers
Top 0.8%
0.8%
28
eBioMedicine
based on 82 papers
Top 9%
0.7%
29
npj Vaccines
based on 18 papers
Top 1%
0.7%
30
The Journal of Infectious Diseases
based on 137 papers
Top 12%
0.7%